Delhi, July 26, 2023 (GLOBE NEWSWIRE) -- US Orphan Drugs Market, Drugs Sales, Price, Dosage & Clinical Trials Insight 2028 Report Highlights:
- US Orphan Drugs Market Opportunity: > USD 150 Billion By 2028
- Orphan Drugs Dosage, Price & Treatment Cost: > 350 Orphan Drug
- Annual & Quarterly Sales Insight (2019 – Q1’2023):> 100 Orphan Drugs
- US Orphan Drugs Reimbursement Scenario: Medicare, Medicaid, Private Insurers
- Active Clinical Trials Insight By Company, Indication & Phase: 1000 Orphan Drugs
- Marketed Orphan Drugs Clinical Insight By Company & Indication: > 400 Orphan Drugs
- Competitive Landscape: 75 Companies
Download Report:
https://www.kuickresearch.com/report-us-orphan-drug-market-size
Rare diseases, by definition, affect a small population of individuals often numbering in the thousands or even fewer. These conditions pose unique challenges for drug development due to the limited patient pool which can make it financially unappealing for pharmaceutical companies to invest it research and investment. To address this gap, the US FDA established the orphan drug designation program. This initiative has played a pivotal role in advancing treatments for rare diseases.
One of the most critical advantages of orphan drug designation is the grant of market exclusivity. Upon FDA approval, an orphan drug receives 7 years of market exclusivity, during which competing drugs for the same rare disease are generally not approved. This exclusivity period provides a crucial window for the drug developer to recover their investment and establish a strong market presence without immediate competition. It creates a favorable environment for pharmaceutical companies to focus on research, development and commercialization efforts knowing that they have a protected space to introduce their innovative therapies.
Market exclusivity resulting from orphan drug designation significantly enhances the market value of a drug. With larger pharmaceutical companies focusing on the development of orphan drugs, their market continues to overtake to the broader pharmaceutical market, making orphan drugs no longer a niche market. The exclusivity period drug developers to command premium pricing and the potential for higher profit margins encourage investors and further financial support for ongoing research and clinical trials. As a result, orphan drug designations play a crucial role in attracting funding and encouraging a robust pipeline of novel medicines for rare diseases.
For instance, recently the US FDA approved Zydus Lifesciences’ ZYIL1 for the treatment of patients with Cryopyrin Associates Periodic Syndrome (CAPS). This orphan drug designation provided ZYIL1 for eligibility for certain incentives for development including tax credits for qualified clinical testing, prescription drug free user exception and finally the seven year marketing exclusivity. In September 2022, the company presented the results from phase I clinical study of ZYIL1 which supported the advancement of ZYIL1 in CAPS patients.
The impact or orphan drug designations extend beyond the domestic market, opening doors for international growth and recognition. The FDA’s rigorous approval process and stringent evaluation criteria provide credibility and establish a solid foundation for global expansion. International regulatory agencies often consider FDA orphan drug designation status when reviewing drug applications. This recognition not only accelerates the approval process but also enhances the drug’s commercial prospects in international markets.
Additionally, many countries have adopted similar orphan drug programs modeled after the US initiative which further streamlines regulatory processes and increases the likelihood of obtaining market exclusivity. International partnerships and collaborations are also facilitated by the orphan drug designations, slowing for clinical trials and market access in multiple countries. These opportunities for global expansion enable drug developers to reach a wider patient population and maximize the impact of their innovative therapies.
The FDA provides additional regulatory assistance to orphan drug developers. This assistance may include consultation meetings, guidance on clinical trial design and expedited review and approval process. These measures aim to streamline the development and regulatory pathway for orphan drugs, ensuring they reach patients in need more efficiently. Moreover, since, the implementation of the US Orphan Drug Act, the orphan drug designation programs has yielded significant process in the field of rare disease treatments. Numerous drugs have received orphan status leading to increased investment and development in areas that were previously overlooked. This has resulted in improved patient outcomes, extended life expectancy and enhanced quality of life for those affected by rare diseases.
The program’s impact has showed the growing number of orphan drugs approved by the FDA each year. In recent years, the FDA has granted orphan drug approvals for a wide range of conditions, including are diseases, cancers, genetic disorders and metabolic disorders. These approvals signify not only scientific advancements but also the positive impact on patients with access to these drugs. In conclusion, the US orphan drug designation program has proven instrumental in driving the development of novel medicines for several rare disorders. The exclusivity granted in the domestic market along with the opportunities for international growth provides drug develops with the incentives needed to pursue breakthrough therapies for rare conditions.
